Lucie Karayan Tapon

Prof. Dr. Lucie Karayan Tapon


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 October 2019 in Cancers
Verified
Journal Article
Open access
PDF file
CECamille Evrard
Camille Evrard
GTGaelle Tachon
Gaelle Tachon
VRViolaine Randrian
Violaine Randrian
LTLucie Karayan Tapon
Lucie Karayan Tapon
DTDavid Tougeron
David Tougeron
Tumor DNA mismatch repair (MMR) deficiency testing is important to the identification of Lynch syndrome and decision making regarding adjuvant chemotherapy in stage II colorectal cancer (CRC) and has become an indispensable test in metastatic tumors due to the high efficacy of immune checkpoint inhibitor (ICI) in deficient MMR (dMMR) tumors. CRCs greatly benefit from this testing as approximately 15% of them are dMMR but only 3% to 5% are at a metastatic stage. MMR status can be determined by two different methods, microsatellite instability (MSI) testing on tumor DNA, and immunohistochemistry of the MMR proteins on tumor tissue. Recent studies have reported a rate of 3% to 10% of discordance between these two tests. Moreover, some reports suggest possible intra- and inter-tumoral heterogeneity of MMR and MSI status. These issues are important to know and to clarify in order to define therapeutic strategy in CRC. This review aims to detail the standard techniques used for the determination of MMR and MSI status, along with their advantages and limits. We review the discordances that may arise between these two tests, tumor heterogeneity of MMR and MSI status, and possible explanations. We also discuss the strategies designed to distinguish sporadic versus germline dMMR/MSI CRC. Finally, we present new and accurate methods aimed at determining MMR/MSI status.

18 January 2021 in Cells
Verified
Journal Article
Open access
PDF file
KMKonstantin Masliantsev
Konstantin Masliantsev
LTLucie Karayan Tapon
Lucie Karayan Tapon
PGPierre-Olivier Guichet
Pierre-Olivier Guichet
The Hippo signaling pathway is a highly conserved pathway involved in tissue development and regeneration that controls organ size through the regulation of cell proliferation and apoptosis. The core Hippo pathway is composed of a block of kinases, MST1/2 (Mammalian STE20-like protein kinase 1/2) and LATS1/2 (Large tumor suppressor 1/2), which inhibits nuclear translocation of YAP/TAZ (Yes-Associated Protein 1/Transcriptional co-activator with PDZ-binding motif) and its downstream association with the TEAD (TEA domain) family of transcription factors. This pathway was recently shown to be involved in tumorigenesis and metastasis in several cancers such as lung, breast, or colorectal cancers but is still poorly investigated in brain tumors. Gliomas are the most common and the most lethal primary brain tumors representing about 80% of malignant central nervous system neoplasms. Despite intensive clinical protocol, the prognosis for patients remains very poor due to systematic relapse and treatment failure. Growing evidence demonstrating the role of Hippo signaling in cancer biology and the lack of efficient treatments for malignant gliomas support the idea that this pathway could represent a potential target paving the way for alternative therapeutics. Based on recent advances in the Hippo pathway deciphering, the main goal of this review is to highlight the role of this pathway in gliomas by a state-of-the-art synthesis.

28 August 2018 in The Journal of Pathology
Verified
Journal Article
Closed access
PDF file
PGPierre-Olivier Guichet
Pierre-Olivier Guichet
KMKonstantin Masliantsev
Konstantin Masliantsev
GTGaëlle Tachon
Gaëlle Tachon
CPChristos Petropoulos
Christos Petropoulos
JGJulie Godet
Julie Godet
LTLucie Karayan Tapon
Lucie Karayan Tapon

1 June 2019 in Laboratory Investigation
Verified
Journal Article
Closed access
PDF file
GTGaelle Tachon
Gaelle Tachon
KMKonstantin Masliantsev
Konstantin Masliantsev
PRPierre Rivet
Pierre Rivet
CPChristos Petropoulos
Christos Petropoulos
JGJulie Godet
Julie Godet
LTLucie Karayan Tapon
Lucie Karayan Tapon

6 June 2020 in Cancers
Verified
Journal Article
Open access
PDF file
AJAudelaure Junca
Audelaure Junca
GTGaelle Tachon
Gaelle Tachon
CECamille Evrard
Camille Evrard
CVClaire Villalva
Claire Villalva
EFEric Frouin
Eric Frouin
DTDavid Tougeron
David Tougeron
Background: In most countries, participation in colorectal cancer (CRC) screening programs with the immunological fecal occult blood test (iFOBT) is low. Mutations of RAS and BRAF occur early in colorectal carcinogenesis and “liquid biopsy” allows detection of mutated circulating tumor DNA (ctDNA). This prospective study aims to evaluate the performance of RAS and BRAF-mutated ctDNA in detecting CRC and advanced adenomas (AA). Methods: One hundred and thirty patients who underwent colonoscopy for suspicion of colorectal lesion were included and divided into four groups: 20 CRC, 39 AA, 31 non-advanced adenoma and/or hyperplastic polyp(s) (NAA) and 40 with no lesion. Mutated ctDNA was analyzed by droplet digital PCR. Results: ctDNA was detected in 45.0% of CRC, in 2.6% of AA and none of the NAA and “no-lesion” groups. All patients with stage II to IV mutated CRC had detectable ctDNA (n = 8/8). Among the mutated AA, only one patient had detectable ctDNA (4.3%), maybe due to limited technical sensitivity or to a low rate of ctDNA or even the absence ctDNA in plasma. Specificity and sensitivity of KRAS- and BRAF-mutated ctDNA for the detection of all CRC and AA were 100% and 16.9%, respectively. Conclusions: ctDNA had high sensitivity in detection of advanced mutated CRC but was unable to sensitively detect AA. ctDNA analysis was easy to perform and readily accepted by the population but requires combination with other circulating biomarkers before replacing iFOBT.

16 December 2017 in Oncotarget
Verified
Journal Article
Open access
PDF file
KMKonstantin Masliantsev
Konstantin Masliantsev
BPBaptiste Pinel
Baptiste Pinel
ABAnaïs Balbous
Anaïs Balbous
PGPierre-Olivier Guichet
Pierre-Olivier Guichet
GTGaëlle Tachon
Gaëlle Tachon
LTLucie Karayan Tapon
Lucie Karayan Tapon
Impact of STAT3 phosphorylation in glioblastoma stem cells radiosensitization and patient outcome Impact of STAT3 phosphorylation in glioblastoma stem cells radiosensitization and patient outcome